Quest Diagnostics outlines $12.065B-$12.105B 2026 revenue outlook while projecting consumer health growth to exceed 30% (NYSE:DGX)

Quest Diagnostics reported a cyber incident involving its Quanum Lab Services Manager system, potentially compromising certain patient records. The company paused access to the system while investigating but stated it has not materially disrupted operations. Quest notified U.S. law enforcement and is taking remedial measures. The company reported $11.04 billion in revenue for 2025. This follows recent cyber incidents at Abbott Labs, which is facing lawsuits.

Quest Diagnostics (DGX) reported Q3 2026 earnings with double-digit revenue growth, but faces challenges. PAMA reimbursement cuts may impact 2027 revenues by 1%. Total revenue per requisition declined 4.2% due to business mix, though it rose 1.7% excluding certain relationships. The company also reported a cybersecurity incident and higher fuel costs. CEO Jim Davis and CFO Sam Samad discussed growth strategies, partnerships, and margin improvements.

Quest Diagnostics (DGX) reported Q3 operating income of $479M, up from $386M YoY. Adjusted EPS rose 15.4% to $3.00. The company expects full-year 2026 revenue of $12.065B-$12.105B. Quest plans to acquire select assets from a health system in the Northeastern U.S. and launched consumer health services via Apple Health app. Management addressed PAMA concerns, estimating a 1% revenue impact in 2027.

Quest Diagnostics (DGX) raised its full-year revenue and earnings guidance after Q3 2026, citing strong performance across physician, hospital, and consumer health channels. Key growth drivers include collaborations, acquisitions, and innovative solutions like Apple Health app integration. The company also announced plans to expand its Alzheimer's disease testing portfolio and improve operational efficiency through automation and AI.

Quest Diagnostics reported 10% Q3 2026 revenue growth, driven by strong performance across commercial channels and partnerships. Consumer health revenue is expected to grow over 30% for the year. The company raised full-year 2026 revenue and EPS guidance, citing sustained demand and AI-driven efficiency gains. Management discussed potential PAMA-related revenue impacts and cybersecurity incidents. They plan to offset PAMA headwinds through cost efficiencies and volume growth.

Quest Diagnostics (DGX) increased its 2026 revenue guidance to $12.065B-$12.105B from $11.95B-$12.05B, and adjusted EPS to $11.25-$11.50 from $11.00-$11.30. The updates were part of the company's Q3 earnings release.